Edwards Lifesciences Co. (NYSE:EW) Shares Purchased by Oppenheimer & Co. Inc.

Oppenheimer & Co. Inc. increased its stake in Edwards Lifesciences Co. (NYSE:EW) by 3.9% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 38,186 shares of the medical research company’s stock after acquiring an additional 1,441 shares during the quarter. Oppenheimer & Co. Inc.’s holdings in Edwards Lifesciences were worth $2,520,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD boosted its stake in shares of Edwards Lifesciences by 57.9% in the first quarter. Price T Rowe Associates Inc. MD now owns 6,516,260 shares of the medical research company’s stock worth $622,695,000 after acquiring an additional 2,390,137 shares during the last quarter. Swedbank AB acquired a new stake in Edwards Lifesciences during the 1st quarter worth $124,511,000. Bank of New York Mellon Corp grew its holdings in shares of Edwards Lifesciences by 4.3% during the second quarter. Bank of New York Mellon Corp now owns 19,782,909 shares of the medical research company’s stock worth $1,827,347,000 after buying an additional 809,605 shares in the last quarter. AustralianSuper Pty Ltd raised its position in shares of Edwards Lifesciences by 17.8% in the third quarter. AustralianSuper Pty Ltd now owns 3,273,416 shares of the medical research company’s stock valued at $216,013,000 after buying an additional 494,604 shares during the last quarter. Finally, AIA Group Ltd lifted its stake in shares of Edwards Lifesciences by 91.7% in the third quarter. AIA Group Ltd now owns 749,524 shares of the medical research company’s stock worth $49,461,000 after buying an additional 358,556 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Up 2.4 %

Shares of NYSE:EW opened at $67.76 on Friday. The firm’s 50-day moving average is $67.44 and its two-hundred day moving average is $76.24. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.46 and a quick ratio of 2.89. Edwards Lifesciences Co. has a 1 year low of $58.93 and a 1 year high of $96.12. The firm has a market capitalization of $39.96 billion, a PE ratio of 9.78, a price-to-earnings-growth ratio of 3.74 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, October 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The company had revenue of $1.35 billion for the quarter, compared to analyst estimates of $1.57 billion. During the same period in the prior year, the business earned $0.59 EPS. The firm’s quarterly revenue was up 8.9% on a year-over-year basis. Analysts predict that Edwards Lifesciences Co. will post 2.57 EPS for the current year.

Insider Buying and Selling

In related news, VP Daveen Chopra sold 1,250 shares of Edwards Lifesciences stock in a transaction that occurred on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the completion of the transaction, the vice president now owns 29,333 shares in the company, valued at $2,051,843.35. The trade was a 4.09 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $65.57, for a total transaction of $327,850.00. Following the completion of the sale, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,077,593.52. This represents a 9.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 41,250 shares of company stock valued at $2,744,438 in the last three months. 1.29% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms have commented on EW. Royal Bank of Canada cut their price objective on shares of Edwards Lifesciences from $85.00 to $75.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Baird R W downgraded Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 25th. Evercore ISI dropped their target price on Edwards Lifesciences from $76.00 to $70.00 and set an “in-line” rating for the company in a report on Tuesday, October 1st. Barclays cut their target price on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a research note on Monday, September 9th. Finally, StockNews.com cut shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Thursday, July 25th. Seventeen equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Edwards Lifesciences has an average rating of “Hold” and a consensus target price of $75.67.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.